About Kansas City AIDS Research Consortium
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Clinical Trials at Kansas City AIDS Research Consortium
During the past decade, Kansas City AIDS Research Consortium conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
No longer available
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia
2018-09-14
2024-08-01
Active, not recruiting
45
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
2018-11-27
2024-10-01
Active, not recruiting
45
A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
2020-05-27
2023-12-14
Active, not recruiting
13
A Long-term Follow-up Study in Subjects Who Received CTX001
2021-01-20
2039-09-01
Enrolling by invitation
114
Study of ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD Versus Host Disease
2020-05-11
2020-05-21
Terminated
1
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
2021-02-24
2025-06-07
Recruiting
180
Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
2021-06-01
2026-12-06
Recruiting
312
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Kansas City AIDS Research Consortium" #1 sponsor was "Glaxo Wellcome" with 2 trials, followed by "Agouron Pharmaceuticals" with 1 trials
sponsored, "Boehringer Ingelheim" with 1 trials sponsored, "Celgene Corporation" with 1 trials sponsored and "Dupont Merck"
with 1 trials sponsored. Other sponsors include -1 different institutions and
companies that sponsored additional 9 trials in total.
Clinical Trials Conditions at Kansas City AIDS Research Consortium
According to Clinical.Site data, the most researched conditions in "Kansas City AIDS Research Consortium" are
"HIV Infections" (10 trials), "HIV Seronegativity" (1 trials) and "HIV Wasting Syndrome" (1 trials). Many other conditions were trialed in "Kansas City AIDS Research Consortium" in a lesser frequency.
Clinical Trials Intervention Types at Kansas City AIDS Research Consortium
Most popular intervention types in "Kansas City AIDS Research Consortium" are "Drug" (8 trials) and "Biological" (2 trials). Other intervention types were less common.
The name of intervention was led by "Indinavir sulfate" (3 trials), "Nelfinavir mesylate" (3 trials), "Zidovudine" (3 trials), "Abacavir sulfate" (2 trials) and "Amprenavir" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Kansas City AIDS Research Consortium
The vast majority of trials in "Kansas City AIDS Research Consortium" are
10 trials for "All" genders.
Clinical Trials Status at Kansas City AIDS Research Consortium
Currently, there are NaN active trials in "Kansas City AIDS Research Consortium".
undefined are not yet recruiting,
undefined are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 9 completed trials in Kansas City AIDS Research Consortium,
1 suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Kansas City AIDS Research Consortium, 1 "Phase 1"
clinical trials were conducted, 5 "Phase 2" clinical
trials and 4 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".